科達利(002850.SZ)擬設立南山分公司
格隆匯5月8日丨科達利(002850.SZ)公佈,公司第三屆董事會第二十次(臨時)會議審議通過了《關於設立南山分公司的議案》,同意在深圳市南山區設立分公司,並授權公司管理層負責辦理此次設立分公司的相關事宜。
分公司名稱:深圳市科達利實業股份有限公司南山分公司;經營範圍:五金製品、鋁蓋板、塑料製品、壓鑄製品、模具、汽車配件的生產、銷售及其它國內商業、物資供銷業、貨物和技術的進出口業務。(依法須經批准的項目,經相關部門批准後方可開展經營活動)。許可經營項目:普通貨運。
此次在南山設立分公司,有利於公司及時獲取行業前沿技術信息,把握市場及行業未來發展機會,同時利於公司吸引研發技術人才,增強公司的技術研發能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.